The Department of Health has asked the National Institute of Health and Care Excellence (NICE) to produce guidance on using topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine in the NHS in England and Wales. The Appraisal Committee has considered the evidence submitted and the views of non-manufacturer consultees and commentators, and clinical specialists and patient experts.
The main recommendations made are Paclitaxel and Pegylated Liposomal Doxorubicin (Caelyx) are recommended. Gemcitabine in combination with Carboplatin, Trabectedin and Topotecan are not recommended.
This document is not NICE's final guidance on these technologies. The recommendations may change after consultation
More information about dates for this appraisal can be found in the full report: Please click on the link below.
Thank you for posting this. Fascinating stuff! I will reread with a glass of wine later for a more detailed understanding.
Thank you Sonia.
Mind boggling!! Its a shame there is not a short version.
Regards Barbara.
Thank you Sonia. This is really interesting. The summary at the end is helpful!
Ann
Thank you Sonia... very interesting love x G x
Hi there...
I've summarised what I think the main findings of the NICE report are. No doubt someone will put me right if I've got this wrong ..
Paclitaxel (Taxol) is recommended as an option for treating recurrent ovarian cancer.
Pegylated liposomal doxorubicin hydrochloride (PLDH) (Caelyx) is recommended as an option for treating recurrent ovarian cancer.
Gemcitabine (Gemzar) in combination with carboplatin is not recommended for treating the first recurrence of platinum-sensitive ovarian cancer.
Trabectedin (Yondelis) in combination with PLDH (Caelyx) is not recommended for treating the first recurrence of platinum-sensitive ovarian cancer.
Topotecan (Hycamtin) is not recommended for treating the first recurrence of platinum-sensitive ovarian cancer.
Topotecan is not recommended for treating platinum-resistant or refractory recurrent ovarian cancer.
Women can have several relapses and need a range of treatment options
The standard treatment for women with platinum-sensitive and partially sensitive disease - platinum-combination chemo ... and Taxol - was used for those with no or little response (platinum-refractory) or platinum resistant disease
Those women who were allergic to platinum were offered an alternative platinum agent such as cisplatin or non-platinum regimes. They sometimes were offered desensitisation (to the drug) treatment
Love Tina x
in reply to
Tina.
Thank you so much for taking the time to summarize the guidance.
I must admit my eyes were getting tired and then I reached the end which was important and forgot what I had read before.
If all our medicines have to go through this long process no wonder we are limited to medications that could give us a better quality of life.
I hope there is a shake up, it has been mentioned but do these things happen?
The guidance is preliminary and will change depending n the feedback they get now.
We will be submitting (again, to say that we advocate that all treatments are available for clinicians to prescribe as they feel appropriate)
We welcome the engagement of the OC community(Hence our posting it here) to tell NICE that restriction is unacceptable, that you as individuals respect and wish your clinicians to be able to treat you as they see fit for your individual circumstances, not a generic diktat! we are each different and our treatment should reflect that. If any of you feel so inclined, we are of course happy to help with your submissions!
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Gemcitabine vs Topotecan 
Has any woman been treated with Docetaxel for gynecological cancer?
Niraparib and NICE update
Any new drug treatments I can ask the doctor about? Running low on options
